Nanang Rudianto Ariefta

Dr. Nanang Rudianto Ariefta

Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Fitoterapia
Verified
Journal Article
Closed access
TSTakuma Suzuki
Takuma Suzuki
NANanang Rudianto Ariefta
Nanang Rudianto Ariefta
TKTakuya Koseki
Takuya Koseki
HFHiroshi Furuno
Hiroshi Furuno
EKEunsang Kwon
Eunsang Kwon
YSYoshihito Shiono
Yoshihito Shiono

1 January 2020 in South African Journal of Botany
Verified
Journal Article
Open access
SAS.A.M. Abdelgaleil
S.A.M. Abdelgaleil
MSM.M.G. Saad
M.M.G. Saad
NANanang Rudianto Ariefta
Nanang Rudianto Ariefta
YSY. Shiono
Y. Shiono

1 June 2018 in Fitoterapia
Verified
Journal Article
Closed access
NANanang Rudianto Ariefta
Nanang Rudianto Ariefta
PKPriska Kristiana
Priska Kristiana
TATakako Aboshi
Takako Aboshi
TMTetsuya Murayama
Tetsuya Murayama
KTKeitaro Tawaraya
Keitaro Tawaraya
YSYoshihito Shiono
Yoshihito Shiono

1 October 2017 in Tetrahedron Letters
Verified
Journal Article
Closed access
NANanang Rudianto Ariefta
Nanang Rudianto Ariefta
PKPriska Kristiana
Priska Kristiana
HNHandojo Hadi Nurjanto
Handojo Hadi Nurjanto
HMHiroyuki Momma
Hiroyuki Momma
EKEunsang Kwon
Eunsang Kwon
YSYoshihito Shiono
Yoshihito Shiono

1 June 2019 in Phytochemistry Letters
Verified
Journal Article
Closed access
TNTomoki Nakamura
Tomoki Nakamura
TSTakuma Suzuki
Takuma Suzuki
NANanang Rudianto Ariefta
Nanang Rudianto Ariefta
TKTakuya Koseki
Takuya Koseki
TATakako Aboshi
Takako Aboshi
YSYoshihito Shiono
Yoshihito Shiono

28 February 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NANanang Rudianto Ariefta
Nanang Rudianto Ariefta
BPBaldorj Pagmadulam
Baldorj Pagmadulam
CNCoh-ichi Nihei
Coh-ichi Nihei
YNYoshifumi Nishikawa
Yoshifumi Nishikawa
The emerging spread of drug-resistant malaria parasites highlights the need for new antimalarial agents. This study evaluated the growth-inhibitory effects of sparsomycin (Sm), a peptidyl transferase inhibitor, against Plasmodium falciparum 3D7 (chloroquine-sensitive strain), P. falciparum K1 (resistant to multiple drugs, including chloroquine), P. yoelii 17XNL (cause of uncomplicated rodent malaria) and P. berghei ANKA (cause of complicated rodent malaria). Using a fluorescence-based assay, we found that Sm exhibited half-maximal inhibitory concentrations (IC50) of 12.07 and 25.43 nM against P. falciparum 3D7 and K1, respectively. In vitro treatment of P. falciparum 3D7 with Sm at 10 or 50 nM induced morphological alteration, blocked parasites in the ring state and prevented erythrocyte reinvasion, even after removal of the compound. In mice infected with P. yoelii 17XNL, the administration of 100 μg/kg Sm for 7 days did not affect parasitemia. Meanwhile, treatment with 300 μg/kg Sm resulted in a significantly lower parasitemia peak (18.85%) than that observed in the control group (40.13%). In mice infected with P. berghei ANKA, both four and seven doses of Sm (300 μg/kg) prolonged survival by 33.33%. Our results indicate that Sm has potential antiplasmodial activities in vitro and in vivo, warranting its further development as an alternative treatment for malaria.